March 30, 2017 at 11 am PT/2 pm ET

 

Using Genetics to Guide Pharmacotherapy

Register to watch on demand (60 minutes)

In this webinar, Phil Empey, PhD, from the University of Pittsburgh, discussed the following:

  • What is pharmacogenomics
  • How you can implement it in your practice
  • Useful resources to help you expand your knowledge

Learning objectives

  • Review core concepts in pharmacogenomics
  • Integrate pharmacogenomics data with clinical variables in order to determine appropriate pharmacotherapy for patients.
  • Recognize the availability of evidence based guidelines that synthesize information relevant for the selection of drug therapy.
  • Appreciate the implications of using pharmacogenomics testing to guide treatment decisions.

More about the speaker

Philip Empey, PhD, is the Associate Director for Pharmacogenomics of the Pitt/UPMC Institute of Personalized Medicine and leads the PreCISE-Rx and Test2Learn teams to implement pharmacogenomics clinical, research and educational initiatives. As a clinician-scientist in the Department of Pharmacy and Therapeutics, Dr. Empey conducts NIH-funded clinical and translational research aimed at understanding the mechanisms of the variability in drug response to improve medication-related outcomes in critically-ill patients. He received his PharmD from the University of Rhode Island and completed PGY1 and PGY2 residencies in Pharmacy Practice and Critical Care at the University of Kentucky. He earned a PhD in Clinical Pharmaceutical Sciences at the University of Kentucky before completing postdoctoral research training at the University of Pittsburgh.

Current research interests include understanding the role/impact of xenobiotic transporters following neurological injury, transporter pharmacogenomics, pharmacogenomics clinical implementation, collection of medication-related phenotype information, and genotype-phenotype discovery. Dr. Empey teaches at the graduate level in pharmacokinetics, pharmacogenomics, and drug transporters in the Schools of Pharmacy, Medicine, and Nursing. He also has a research interest in innovative educational models to transform pharmacogenomics education such as those deployed in Test2Learn and a national pharmacogenomics training program.

* The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include both reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person's overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of 44 variants in the BRCA1 and BRCA2 genes. The report describes if a person's genetic result is associated with an increased risk of developing breast cancer and ovarian cancer and may be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers. The variants included in this report do not represent the majority of the BRCA1/BRCA2 variants in people of most ethnicities. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. This report is for over-the-counter use by adults over the age of 18, and provides genetic information to inform discussions with a healthcare professional. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action. For important information and limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/

**23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Our SLCO1B1 Pharmacogenetics report provides certain information about variants associated with the processing of some therapeutics and provides interpretive drug information regarding the potential effect of simvastatin therapy. Our DPYD Pharmacogenetics report does not describe the association between detected variants and any specific therapeutic. Results for DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetic reports, visit 23andme.com/test-info/pharmacogenetics/